Literature DB >> 9933658

A PET study of 18FDG uptake in soft tissue masses.

M A Lodge1, J D Lucas, P K Marsden, B F Cronin, M J O'Doherty, M A Smith.   

Abstract

A study was performed with the aim of investigating some of the methodological factors affecting the ability of quantitative 2-[18F]-fluoro-2-deoxy-d-glucose (FDG) positron emission tomography to assess tumour malignancy. Twenty-nine patients with soft tissue masses were studied using a 6-hour scanning protocol and various indices of glucose metabolism were compared with histological grade. Significant differences were observed in the time-activity response of benign and high-grade tumours. High-grade sarcomas were found to reach a peak activity concentration approximately 4 h after injection whereas benign lesions reached a maximum within 30 min. This translated to improved differentiation between these two tumour types using a standard uptake value (SUV) derived from images acquired at later times. An SUV measured 4 h post-injection was found to be as useful an index of tumour malignancy as the metabolic rate of FDG determined using either Patlak or non-linear regression techniques. Each of these indices had a sensitivity and specificity of 100% and 76% respectively for the discrimination of high-grade sarcomas from benign tumours.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9933658     DOI: 10.1007/s002590050355

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  66 in total

1.  FDG-PET for preoperative differential diagnosis between benign and malignant soft tissue masses.

Authors:  J Aoki; H Watanabe; T Shinozaki; K Takagishi; M Tokunaga; Y Koyama; N Sato; K Endo
Journal:  Skeletal Radiol       Date:  2003-01-24       Impact factor: 2.199

2.  Clinical significance of primary lesion FDG uptake for choice between oesophagectomy and endoscopic submucosal dissection for resectable oesophageal squamous cell carcinomas.

Authors:  Masatoyo Nakajo; Masayuki Nakajo; Atsushi Tani; Yoriko Kajiya; Shunji Shimaoka; Akio Matsuda; Tatsuyuki Nioh; Tohru Nihara; Toyokuni Suenaga; Sadao Tanaka; Hiroshi Shirahama; Michiyo Higashi; Chihaya Koriyama
Journal:  Eur Radiol       Date:  2011-07-13       Impact factor: 5.315

3.  Partial volume correction of standardized uptake values and the dual time point in FDG-PET imaging: should these be routinely employed in assessing patients with cancer?

Authors:  Sandip Basu; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10       Impact factor: 9.236

4.  The role of [18F]-fluorodeoxyglucose positron emission tomography in predicting plexiform neurofibroma progression.

Authors:  Michael J Fisher; Sandip Basu; Eva Dombi; Jian Q Yu; Brigitte C Widemann; Avrum N Pollock; Avital Cnaan; Hongming Zhuang; Peter C Phillips; Abass Alavi
Journal:  J Neurooncol       Date:  2007-12-11       Impact factor: 4.130

5.  Dual-time points (18)F-FDG PET/CT imaging in detection of bone metastases from hepatocellular carcinoma.

Authors:  Xueren Zhao; Alex Yi; George Ariza; Lee Salcido
Journal:  Int J Clin Exp Med       Date:  2013-01-26

6.  Prediction of biological characteristics of breast cancer using dual-phase FDG PET/CT.

Authors:  Shinsuke Sasada; Norio Masumoto; Eri Suzuki; Satoshi Sueoka; Noriko Goda; Keiko Kajitani; Akiko Emi; Takayuki Kadoya; Morihito Okada
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-16       Impact factor: 9.236

7.  Peripheral nerve schwannoma: two cases exhibiting increased FDG uptake in early and delayed PET imaging.

Authors:  Kenichiro Hamada; Takafumi Ueda; Ichiro Higuchi; Atsuo Inoue; Noriyuki Tamai; Akira Myoi; Yasuhiko Tomita; Katsuyuki Aozasa; Hideki Yoshikawa; Jun Hatazawa
Journal:  Skeletal Radiol       Date:  2004-10-09       Impact factor: 2.199

8.  [18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1.

Authors:  Victoria S Warbey; Rosalie E Ferner; Joel T Dunn; Eduardo Calonje; Michael J O'Doherty
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-14       Impact factor: 9.236

9.  Usefulness of additional delayed regional F-18 Fluorodeoxy-Glucose Positron Emission Tomography in the lymph node staging of Non-Small Cell Lung Cancer patients.

Authors:  Young So; June-Key Chung; Jae Min Jeong; Dong Soo Lee; Myung Chul Lee
Journal:  Cancer Res Treat       Date:  2005-04-30       Impact factor: 4.679

Review 10.  Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis.

Authors:  Sugama Chicklore; Vicky Goh; Musib Siddique; Arunabha Roy; Paul K Marsden; Gary J R Cook
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-10-13       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.